Real-world Outcomes of Efgartigimod in AChR-Positive Generalized Myasthenia Gravis: Response Patterns, Predictors, and Treatment Strategies (S14.002)

Lior Fuchs; Ifat Vigiser; Hadar Kolb; Keren Regev; Vivian Drory; Amir Dori; David Magalashvili; Tal Caller; Gilad Kenan; Yana Mechnik Steen; Mark Hellmann; Adi Wilf-Yarkoni; Tal Friedman Korn; Adi Vaknin Dembinsky; Alaa Bsoul; Shahar Shelly; Arnon Karni

doi:10.1212/wnl.0000000000212884

June 9, 2026Neurology

Real-world Outcomes of Efgartigimod in AChR-Positive Generalized Myasthenia Gravis: Response Patterns, Predictors, and Treatment Strategies (S14.002)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to assess the long-term clinical outcomes and efficacy predictors of efgartigimod in patients with AChR-positive generalized myasthenia gravis.
Evaluated long-term clinical outcomes of efgartigimod for AChR-positive generalized myasthenia gravis.
Analyzed treatment patterns and predictors of efficacy in patients receiving this therapy.
Patients receiving efgartigimod showed significant improvement in clinical outcomes over the long term.
Certain predictors were identified that could indicate better response patterns to the treatment.

Implication

Evaluates long-term outcomes in generalized myasthenia gravis, suggesting effective treatment strategies.

Abstract

To evaluate long-term clinical outcomes, treatment patterns, and predictors of efficacy of efgartigimod in acetylcholine receptor antibody–positive generalize myasthenia gravis (gMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fuchs et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055e14 https://doi.org/10.1212/wnl.0000000000212884

View Full Paper

Ask AI

Bookmark

Share

Real-world Outcomes of Efgartigimod in AChR-Positive Generalized Myasthenia Gravis: Response Patterns, Predictors, and Treatment Strategies (S14.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world Outcomes of Efgartigimod in AChR-Positive Generalized Myasthenia Gravis: Response Patterns, Predictors, and Treatment Strategies (S14.002)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading